|
2006 Key Highlights
2006 was a year in which we delivered strong performance and maintained leadership positions across our businesses, reaching a number of important milestones.
Q1
- Created Abbott Nutrition International and later globalized our nutrition business to strengthen our international reach in rapidly growing markets, such as China, Southeast Asia and Latin America.
- Received FDA clearance to market FreeStyle Freedom, an easy-to-read, easy-to-hold blood glucose meter, which offers virtually pain-free testing.
Q2
- Acquired Guidant’s vascular business, which, combined with Abbott’s vascular business, created a leading vascular device company.
- Launched Humira for ankylosing spondylitis, a form of arthritis affecting the spine and the third new indication for Humira.
- Improved convenience with the U.S. launch of the Humira Pen, a one-touch device that offers patients an easier way to self-administer Humira at home just twice a month.
Q3
- Submitted global regulatory applications for the approval of Humira for the treatment of Crohn’s disease.
- Announced a collaboration with AstraZeneca to develop a fixed-dose combination lipid management therapy of Crestor and Abbott’s TriCor or ABT-335, our next-generation fenofibrate.
Q4
- Launched Xience V, our next-generation drug-eluting stent, in Europe and Asia. Positive clinical results for Xience V demonstrated superiority to a leading drug-eluting stent, with respect to the study’s primary endpoint.
- Acquired Kos Pharmaceuticals, broadening our presence in cholesterol management with HDL-raising Niaspan and expanding our mid- to late-stage pipeline.
|
Page Top
Previous
